Relief Therapeutics Holding AG Market Cap ($36.33 Million)
Market Cap & Net Worth: Relief Therapeutics Holding AG (RLF)
Relief Therapeutics Holding AG market cap. Relief Therapeutics Holding AG (SW:RLF) has a market capitalization of $36.33 Million (CHF28.73 Million) as of November 4, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #22861 globally and #204 in its home market, demonstrating a 3.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Relief Therapeutics Holding AG's stock price CHF2.89 by its total outstanding shares 12591919 (12.59 Million). Also see Relief Therapeutics Holding AG (RLF) cash conversion ratio for how efficiently the company converts equity into cash flow.
Relief Therapeutics Holding AG Market Cap History (2015–2025)
Relief Therapeutics Holding AG market cap history from 2015 to 2025. Data shows change from $318.39 Million to $45.93 Million (-17.36% CAGR). Check Relief Therapeutics Holding AG stock price for real-time trading data and today's change.
Relief Therapeutics Holding AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Relief Therapeutics Holding AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Relief Therapeutics Holding AG (RLF) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7.96x
Relief Therapeutics Holding AG's market cap is 7.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $318.39 Million | $256.12K | -$9.15 Million | 1243.15x | N/A |
| 2016 | $191.04 Million | $15.00K | -$16.83 Million | 12735.67x | N/A |
| 2018 | $33.11 Million | $567.00K | -$436.00K | 58.40x | N/A |
| 2021 | $396.08 Million | $3.32 Million | -$34.70 Million | 119.27x | N/A |
| 2022 | $191.04 Million | $6.08 Million | -$50.79 Million | 31.42x | N/A |
| 2023 | $31.68 Million | $6.03 Million | -$98.18 Million | 5.25x | N/A |
| 2024 | $67.02 Million | $8.42 Million | -$17.12 Million | 7.96x | N/A |
Competitor Companies of RLF by Market Capitalization
Companies near Relief Therapeutics Holding AG in the global market cap rankings as of November 4, 2026. Also see RLF asset base for a full breakdown of the balance sheet.
Key companies related to Relief Therapeutics Holding AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Relief Therapeutics Holding AG (2015–2025)
Market capitalization of Relief Therapeutics Holding AG from 2015 to today. Between 2015 and today, Relief Therapeutics Holding AG's market cap moved from $318.39 Million to $ 45.93 Million, with a yearly change of -17.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | CHF45.93 Million | -31.47% |
| 2024 | CHF67.02 Million | +111.56% |
| 2023 | CHF31.68 Million | -83.42% |
| 2022 | CHF191.04 Million | -51.77% |
| 2021 | CHF396.08 Million | -76.88% |
| 2020 | CHF1.71 Billion | +26800.00% |
| 2019 | CHF6.37 Million | -80.77% |
| 2018 | CHF33.11 Million | -48.00% |
| 2017 | CHF63.68 Million | -66.67% |
| 2016 | CHF191.04 Million | -40.00% |
| 2015 | CHF318.39 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Relief Therapeutics Holding AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.33 Million USD |
| MoneyControl | $36.33 Million USD |
| MarketWatch | $36.33 Million USD |
| marketcap.company | $36.33 Million USD |
| Reuters | $36.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Relief Therapeutics Holding AG
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium ph… Read more